Your browser doesn't support javascript.
loading
Treatment-focused Ebola trials, supportive care and future of filovirus care.
Keshtkar-Jahromi, Maryam; Martins, Karen A O; Cardile, Anthony P; Reisler, Ronald B; Christopher, George W; Bavari, Sina.
Afiliación
  • Keshtkar-Jahromi M; a Division of Infectious Diseases, Department of Medicine , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
  • Martins KAO; b Division of Medicine , United States Army Medical Research Institute of Infectious Diseases , Frederick , MD , USA.
  • Cardile AP; b Division of Medicine , United States Army Medical Research Institute of Infectious Diseases , Frederick , MD , USA.
  • Reisler RB; b Division of Medicine , United States Army Medical Research Institute of Infectious Diseases , Frederick , MD , USA.
  • Christopher GW; c Project Management Office, Medical Countermeasure systems , Fort Belvoir , VA , USA.
  • Bavari S; b Division of Medicine , United States Army Medical Research Institute of Infectious Diseases , Frederick , MD , USA.
Expert Rev Anti Infect Ther ; 16(1): 67-76, 2018 01.
Article en En | MEDLINE | ID: mdl-29210303
INTRODUCTION: During the 2014-2016 Ebolavirus (EBOV) outbreak, several candidate therapeutics were used in EBOV-infected patients in clinical trials and under expanded access for emergency use. This review will focus briefly on medications used during the outbreak. We will discuss current therapeutic candidates and their status and will then turn to a related and essential topic: supportive care and the standard of care for filovirus infected patients. Potential benefits and pitfalls of combination therapies for filoviruses will be discussed. Areas covered: Clinical trials of therapeutics targeting EBOV; clinical usage of therapeutics during recent EBOV outbreak; potential need for combination therapy; role of supportive care in treatment of Ebola virus disease (EVD). Expert commentary: In the absence of another large scale EBOV outbreak, the path to therapeutic product licensure in the United States of America (USA) would need to be via the FDA Animal Rule. However, human data may be needed to supplement animal data. The future of filovirus therapeutics may therefore benefit by establishing the ability to implement clinical trials in an outbreak setting in a timely fashion. Supportive care guidelines for filovirus infection should be defined and established as standard of care for treatment of EVD.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Brotes de Enfermedades / Fiebre Hemorrágica Ebola Tipo de estudio: Guideline Límite: Animals / Humans Idioma: En Revista: Expert Rev Anti Infect Ther Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Brotes de Enfermedades / Fiebre Hemorrágica Ebola Tipo de estudio: Guideline Límite: Animals / Humans Idioma: En Revista: Expert Rev Anti Infect Ther Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido